Literature DB >> 8183558

Fusion with E2A alters the transcriptional properties of the homeodomain protein PBX1 in t(1;19) leukemias.

D P LeBrun1, M L Cleary.   

Abstract

The t(1;19) chromosomal translocation is observed in pre-B cell acute lymphoblastic leukemias and results in expression of chimeric E2A-PBX1 proteins that contain transcriptional activation domains from E2A and the homeodomain of PBX1. Since homeodomains mediate DNA-binding, a potential model for the action of E2A-PBX1 is that it disrupts the transcriptional regulation of genes normally controlled by PBX1 or its closely-related family members PBX2 or PBX3. Using a binding site selection assay, we identified a consensus nucleotide sequence ATCAATCA specifically bound by the PBX1 homeodomain and those of its closely-related family members PBX2 and PBX3. An endogenous protein with the properties of PBX3b specifically bound to this sequence in nuclear extracts of precursor B cells. Transfection of reporter genes containing PBX binding sites linked to a minimal promoter demonstrated transactivation by E2A-PBX1 fusion protein dependent upon presence of the homeodomain. In contrast, wild-type PBX proteins were incapable of activating transcription. The striking differences in transcriptional properties of fusion and wild-type PBX proteins provides strong functional evidence for the importance of aberrant transcriptional regulation in the genesis of t(1;19)-bearing leukemias.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8183558

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

1.  Critical role for a single leucine residue in leukemia induction by E2A-PBX1.

Authors:  Richard Bayly; Takayuki Murase; Brandy D Hyndman; Rachel Savage; Salima Nurmohamed; Kim Munro; Richard Casselman; Steven P Smith; David P LeBrun
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

2.  Pbx modulation of Hox homeodomain amino-terminal arms establishes different DNA-binding specificities across the Hox locus.

Authors:  C P Chang; L Brocchieri; W F Shen; C Largman; M L Cleary
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

3.  Meis proteins are major in vivo DNA binding partners for wild-type but not chimeric Pbx proteins.

Authors:  C P Chang; Y Jacobs; T Nakamura; N A Jenkins; N G Copeland; M L Cleary
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

4.  Pbx-1 Hox heterodimers bind DNA on inseparable half-sites that permit intrinsic DNA binding specificity of the Hox partner at nucleotides 3' to a TAAT motif.

Authors:  P S Knoepfler; Q Lu; M P Kamps
Journal:  Nucleic Acids Res       Date:  1996-06-15       Impact factor: 16.971

5.  Pbx raises the DNA binding specificity but not the selectivity of antennapedia Hox proteins.

Authors:  S T Neuteboom; C Murre
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

6.  E2a-Pbx1 induces aberrant expression of tissue-specific and developmentally regulated genes when expressed in NIH 3T3 fibroblasts.

Authors:  X Fu; M P Kamps
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

7.  A gene fusion at a homeobox locus: alterations in leaf shape and implications for morphological evolution.

Authors:  J J Chen; B J Janssen; A Williams; N Sinha
Journal:  Plant Cell       Date:  1997-08       Impact factor: 11.277

8.  Transformation properties of the E2a-Pbx1 chimeric oncoprotein: fusion with E2a is essential, but the Pbx1 homeodomain is dispensable.

Authors:  K Monica; D P LeBrun; D A Dedera; R Brown; M L Cleary
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

9.  A structural model for a homeotic protein-extradenticle-DNA complex accounts for the choice of HOX protein in the heterodimer.

Authors:  S K Chan; R S Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

Review 10.  Mechanisms of chromosomal rearrangement in the human genome.

Authors:  Albert G Tsai; Michael R Lieber
Journal:  BMC Genomics       Date:  2010-02-10       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.